NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Acquires 49,400 Shares

Posted by Stuart Ham on Apr 17th, 2025

NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Get Free Report) major shareholder Poplar Point Capital Partners bought 49,400 shares of the firm’s stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $0.61 per share, with a total value of $30,134.00. Following the completion of the transaction, the insider now directly owns 950,000 shares in the company, valued at $579,500. This represents a 5.49 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

On Friday, January 31st, Poplar Point Capital Partners acquired 70,685 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.65 per share, with a total value of $45,945.25.
On Monday, January 27th, Poplar Point Capital Partners bought 31,703 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average cost of $0.69 per share, for a total transaction of $21,875.07.
On Thursday, February 20th, Poplar Point Capital Partners purchased 1,836 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.63 per share, with a total value of $1,156.68.
On Tuesday, February 18th, Poplar Point Capital Partners acquired 3,222 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.66 per share, for a total transaction of $2,126.52.
On Monday, February 3rd, Poplar Point Capital Partners acquired 2,597 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.64 per share, with a total value of $1,662.08.
On Friday, March 7th, Poplar Point Capital Partners bought 102 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.55 per share, with a total value of $56.10.
On Tuesday, March 4th, Poplar Point Capital Partners purchased 4,000 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.58 per share, for a total transaction of $2,320.00.
On Thursday, February 27th, Poplar Point Capital Partners acquired 385 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.61 per share, with a total value of $234.85.
On Tuesday, February 25th, Poplar Point Capital Partners bought 25,033 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.62 per share, for a total transaction of $15,520.46.
On Friday, March 14th, Poplar Point Capital Partners purchased 25,511 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average price of $0.63 per share, with a total value of $16,071.93.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY opened at $0.59 on Thursday. The firm has a market cap of $3.42 million, a price-to-earnings ratio of -0.01 and a beta of 0.90. The firm has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.63. NovaBay Pharmaceuticals, Inc. has a 52 week low of $0.36 and a 52 week high of $9.08.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of NovaBay Pharmaceuticals in a report on Thursday, April 10th. They set a “hold” rating on the stock.

View Our Latest Report on NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Company Profile

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.